Walleye Capital
CLYM

Walleye Capital’s Climb Bio CLYM Stock Holding History

Walleye Capital’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,000
Closed -$30.1K – 5249
2025
Q3 		$30.1K Buy
+15,000
New +$27.9K ﹤0.01% 4137
2025
Q1 		– Sell
-62,039
Closed -$112K – 5304
2024
Q4 		$112K Buy
+62,039
New +$224K ﹤0.01% 4090
2024
Q3 		– Sell
-196,390
Closed -$1.4M – 5986
2024
Q2 		$1.4M Buy
+196,390
New +$1.31M ﹤0.01% 2486

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Walleye Capital's CLYM Position: Q4 2025 in Review

Walleye Capital sold out of Climb Bio (CLYM) in Q4 2025, closing a stake of 15,000 shares — an estimated $30.1K sold.

Walleye Capital first reported a position in CLYM in Q2 2024 and held it in 3 quarters. The position peaked at $1.4M in Q2 2024. 65 funds tracked by Wall St. Rank hold CLYM as of Q4 2025.

  • Walleye Capital reported no remaining Climb Bio position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 15,000 Climb Bio shares in Q4 2025, an estimated $30.1K.
  • Walleye Capital first reported a position in Climb Bio in Q2 2024 and held it in 3 quarters.
  • Walleye Capital's Climb Bio position peaked at $1.4M in Q2 2024.
  • 65 funds tracked by Wall St. Rank held Climb Bio as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.